.png)
Pluri (Pluristem)
Placental cell therapy (PLX-R18) for acute radiation syndrome; DoD/NIAID nuclear countermeasure
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Pluri is positioned as a multi-vertical cell-therapy and cell-manufacturing platform company, with a core regenerative medicine franchise and expansion into CDMO, food tech, and agtech. The strategy appears to emphasize monetizing proprietary 3D cell expansion technology through both therapeutic development and partnerships rather than relying on a single-product business model.[3][4][13][14]
Efficiency Ratio
The company shows strong intellectual-property and platform output relative to its modest employee base, but commercial conversion appears moderate because most visible activity remains development- and partnership-oriented rather than scaled recurring revenue.[7][9][13]
Evidence Signals
Public company with a moderate digital footprint: official website, LinkedIn presence with 16,417 followers, and investor materials available online.
Investor presentation identifies the company as NASDAQ: PLUR and headquartered in Matam Park, Haifa.
Company materials emphasize pursuing partnerships that leverage its 3D cell-based technology across multiple industries.
Operates a GMP cell manufacturing facility and positions itself as a CDMO focused on cell therapy manufacturing and process development.
Public listings describe a portfolio of over 140 granted patents across approximately 52 countries.
Pluri announced completion of the first phase of its Resbiomed program, indicating continued product-development activity.
Employee estimates cluster around 106-135 employees, indicating a small-to-mid-sized operating footprint.
- About
- Israeli cell-therapy / biotech company (HQ Haifa, Israel — MATAM Park; Nasdaq/TASE: PLUR; formerly Pluristem Therapeutics; founded 2003; CEO Yaky Yanay). Pluri's core asset is a patented 3D cell-expansion platform that mass-produces cells consistently and at scale; the company applies it across TWO arms — regenerative medicine AND food-tech/sustainability (cultivated-meat / agtech). Its defense-relevant program is PLX-R18 (avoplacel), an off-the-shelf intramuscular placental cell therapy for hematopoietic acute radiation syndrome (H-ARS) — radiation poisoning from a nuclear/radiological accident, attack or warfare. PLX-R18 is developed under the FDA Animal Rule toward the US Strategic National Stockpile (IND cleared, Orphan Drug Designation) and is actively funded/studied by the US DoD's AFRRI/USUHS and the NIH's NIAID (a 3-year contract signed 2023, ~$4.2M; NIAID exercised its 2nd-year option in 2024); in Nov 2024 Pluri began assessing mass-production readiness amid rising nuclear-threat concerns. Animal studies showed survival rising from ~29% (control) to ~97% (treated). Important: Pluri's center of gravity is a broad cell-expansion platform (incl. food-tech), NOT a defense pure-play — it earns its defense-health place specifically on the active, government-funded PLX-R18 radiation-countermeasure program.
- Tags
- #radiation #ARS #celltherapy #placental #medicalcountermeasure #dod #niaid #nuclear #cbrn #rxbio #dualuse